Can Aqualase replace phaco?

Article

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification.

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification, according to a report published in the February issue of Eye.

Laurence Whitefield and colleagues from Queen Mary's Hospital, Kent, UK, enrolled 33 subjects (mean age 71.4 years) to undergo cataract surgery using Aqualase through a 3.2 mm corneal incision. Grade of nucleus, nuclear removal technique and intraoperative complications were recorded.

The researchers found that Aqualase is capable of removing cataracts up to nuclear sclerosis 2+ fairly easily. Nuclei that were graded 2+ or greater were more technically difficult and conversion to ultrasound phacoemulsification was required in one case. Of the 33 procedures there were just two cases of posterior capsule rupture. One occurred during nucleus removal and the other was unrelated to Aqualase. A total of 96% of the subjects, without preoperative comorbidity, achieved 6/9 or better postoperatively.

The researchers feel that Aqualase does have an advantage over phacoemulsification, as it carries less risk of damage to the posterior capsule. Additionally, the method is similar enough to phacoemulsification to ensure that the learning curve is not too steep. However, they emphasize that Aqualase it is not completely risk free as rupture is possible with the floor pedal in position two.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.